Ownership and insider activity for Belite Bio, Inc (BLTE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Price
| Price | $169.21 |
| Market Cap | $6.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 2,635 | $475K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 2,587 | $469K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 3,413 | $623K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 4,955 | $908K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 6,252 | $1.2M |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 4,593 | $851K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 7,800 | $1.5M |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 6,200 | $1.2M |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 3,045 | $573K |
| 2026-09-04 | Lin Yu-Hsin | S-Sale | 8,955 | $1.7M |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.6M | $17.3M | $42.1M | $88.2M | $31.7M | $352.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | $113.5M | $139.5M |
| Receivables | $40000 | $23000 | $19000 | $867000 | $594000 | $718000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.7M | $17.4M | $42.8M | $89.9M | $147.1M | $494.3M |
| Property, Plant & Equipment | $66000 | $94000 | $1.3M | $1.3M | $965000 | $777000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $31000 | $3.3M | $4.0M | $4.9M |
| Total Assets | $25.7M | $18.3M | $44.3M | $94.6M | $152.1M | $780.6M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $972000 | $1.6M | $2.1M | $3.6M | $6.0M | $9.9M |
| Long-term Debt | $31.8M | $31.8M | 0 | 0 | 0 | 0 |
| Total Liabilities | $32.8M | $33.4M | $2.8M | $4.2M | $6.3M | $10.1M |
| Retained Earnings | -$17.6M | -$27.2M | -$39.9M | -$71.5M | -$107.6M | -$185.3M |
| Total Equity | -$7.0M | -$15.1M | $41.5M | $90.4M | $145.8M | $770.5M |
| Total Debt | $31.8M | $31.8M | $866000 | $886000 | $537000 | $429000 |
| Net Debt | $6.2M | $14.5M | -$41.2M | -$87.3M | -$144.6M | -$492.0M |
| Working Capital | $24.7M | $15.8M | $40.7M | $86.3M | $141.0M | $484.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |
Profitability
| Return on Equity | -10.07% |
| Return on Invested Capital | -10.92% |
| Return on Assets | -9.94% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACAD · ADMA · ARQT · CRNX · DYN · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks